

HIBERNATION THERAPEUTICS

Innovations from Nature to Medicine



Contact: Beth Wilson
478-744-9994 x6211
bethwilson@t3med.com

Hibernation Therapeutics and B. Braun CAPS® Get to the Heart of Patient Safety *Patented Adenocaine™ Technology Shared with CAPS®*

Atlanta – November 16, 2009 – [Hibernation Therapeutics USA, LLC](#) has signed an exclusive sublicensing agreement with [Central Admixture Pharmacy Services, Inc. \(CAPS®\)](#), a [B. Braun Medical Inc.](#) (B. Braun) Company for the compounding and distribution of its patented Adenocaine™ technology, the world's first non-depolarising cardioplegia.

A biotech company founded by Geoffrey Dobson MS, PhD, who also serves as its Chief Scientific Officer, Hibernation Therapeutics (HT) has developed and wholly owns the intellectual property for a number of drug compounds, including Adenocaine™ cardioplegia, which is used to induce, maintain arrest and animate the heart without the use of high potassium and has demonstrated significant cardioprotective benefits.

“A growing unmet need in cardiac surgery is finding innovative ways to improve cardioprotection,” said Dr. Dobson. “For more than 40 years surgeons and scientists have sought alternatives to advancing cardioplegia, but until now, no new arrest paradigm has seriously challenged the current standard of high potassium based cardioplegia. The Adenocaine™ technology places the heart in a more 'natural' state of suspended animation similar to that of a hibernating animal, making cardiac surgery safer for the patient, more predictable for the surgeon and economically compelling for hospitals and other purchasers of health care.”

Adenocaine's™ patented formulation has shown increased myocardial protection and improved outcomes in preclinical studies and physicians are observing similar results during clinical use, in comparison to standard high potassium cardioplegia.

“Choosing CAPS®, the largest and one of the most respected admixture pharmacies in the United States, as the compounding and distribution partner for Adenocaine™ cardioplegia was a simple choice,” said David C. Field, Chief Executive Officer for Hibernation Therapeutics. “Through this relationship with CAPS®, Hibernation Therapeutics will be able to make the benefits of this pharmaceutical available on a global scale while the company focuses on developing broader applications of the Adenocaine™ technology.”

For more information on Hibernation Therapeutics, its Adenocaine™ technologies and intellectual property, please visit www.Adenocaine.com.

Adenocaine is a registered trademark of Hibernation Therapeutics Ltd.

About Central Admixture Pharmacy Services (CAPS®)

State-licensed and an FDA-registered manufacturer, CAPS® makes daily deliveries from an unrivaled 22 locations nationwide. Making over 200,000 local deliveries annually, CAPS pharmacies reliably operate 365 days a year to dispense labeled, patient specific and anticipatory IV prescriptions to an ever growing family of outsourcing pharmacy providers. CAPS® is a B. Braun company. For more information on CAPS, please visit www.capspharmacy.com/Adenocaine